Cargando…
A Review of Clinical Influenza A and B Infections With Reduced Susceptibility to Both Oseltamivir and Zanamivir
Anti-influenza drugs play major roles in the management of severe influenza infections. Neuraminidase inhibitors (NAIs), which are active against all influenza A subtypes and the 2 major influenza B lineages, constitute the only class of antivirals recommended for the control of influenza epidemics...
Autores principales: | Abed, Yacine, Boivin, Guy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5569976/ https://www.ncbi.nlm.nih.gov/pubmed/28852674 http://dx.doi.org/10.1093/ofid/ofx105 |
Ejemplares similares
-
Comparison of efficacy and safety of oseltamivir and zanamivir in pandemic influenza treatment
por: Tuna, Nazan, et al.
Publicado: (2012) -
Efficacy of oseltamivir compared with zanamivir in COPD patients with seasonal influenza virus infection: a randomized controlled trial
por: Li, Min, et al.
Publicado: (2020) -
A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir
por: Matsuzaki, Yoko, et al.
Publicado: (2010) -
Reduced Susceptibility to Neuraminidase Inhibitors in Influenza B Isolate, Canada
por: Abed, Yacine, et al.
Publicado: (2019) -
Oseltamivir/zanamivir: Lack of efficacy leading to fatal influenza A (H1N1) infection: case report
Publicado: (2013)